Tudor Investment Corp ET AL Makes New $492,000 Investment in Alkermes plc (NASDAQ:ALKS)

Tudor Investment Corp ET AL purchased a new position in shares of Alkermes plc (NASDAQ:ALKS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 17,120 shares of the company’s stock, valued at approximately $492,000.

Other institutional investors have also recently made changes to their positions in the company. Natixis Advisors LLC boosted its stake in shares of Alkermes by 36.8% during the fourth quarter. Natixis Advisors LLC now owns 49,922 shares of the company’s stock valued at $1,436,000 after purchasing an additional 13,432 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Alkermes by 147.4% during the 4th quarter. JPMorgan Chase & Co. now owns 889,472 shares of the company’s stock valued at $25,581,000 after acquiring an additional 529,962 shares in the last quarter. Barclays PLC increased its holdings in shares of Alkermes by 108.8% in the 3rd quarter. Barclays PLC now owns 423,931 shares of the company’s stock valued at $11,867,000 after acquiring an additional 220,893 shares during the period. Savant Capital LLC raised its position in shares of Alkermes by 11.6% in the 4th quarter. Savant Capital LLC now owns 11,075 shares of the company’s stock worth $319,000 after acquiring an additional 1,152 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Alkermes by 558.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company’s stock worth $85,000 after purchasing an additional 2,502 shares during the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ALKS. Royal Bank of Canada lifted their target price on Alkermes from $39.00 to $40.00 and gave the company a “sector perform” rating in a research note on Friday, May 2nd. StockNews.com lowered shares of Alkermes from a “strong-buy” rating to a “buy” rating in a research note on Monday. HC Wainwright reissued a “neutral” rating on shares of Alkermes in a research report on Friday, May 2nd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, March 27th. Finally, UBS Group reissued a “sector perform” rating on shares of Alkermes in a research report on Monday, April 28th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.33.

Insider Buying and Selling

In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the transaction, the executive vice president now owns 57,875 shares in the company, valued at $2,056,298.75. This represents a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.40% of the stock is owned by company insiders.

Alkermes Stock Up 0.0 %

Alkermes stock opened at $30.40 on Friday. The company’s 50 day moving average is $31.04 and its two-hundred day moving average is $30.51. The firm has a market cap of $5.01 billion, a PE ratio of 14.01, a price-to-earnings-growth ratio of 2.20 and a beta of 0.51. Alkermes plc has a 52-week low of $22.90 and a 52-week high of $36.45.

Alkermes (NASDAQ:ALKS) last issued its earnings results on Thursday, May 1st. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.19). The firm had revenue of $306.51 million during the quarter, compared to analyst estimates of $307.53 million. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. The firm’s revenue was down 12.6% compared to the same quarter last year. During the same period last year, the business earned $0.43 EPS. On average, equities research analysts anticipate that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.